Reduction of anterior uveitis flares in patients with axialspondyloarthritis on certolizumab pegol treatment: final 2-year results from themulticenter phase IV C-VIEW study

• Published in: Therapeutic advances in musculoskeletal disease 2021-01, Vol.13
• Main Authors: van der Horst-Bruinsma Irene E, van Bentum Rianne E, Verbraak, Frank D, Deodhar Atul, Rath, Thomas, Hoepken Bengt, Irvin-Sellers, Oscar, Thomas, Karen, Bauer, Lars, Rudwaleit, Martin
• Format: Article
• Language: English
• Subjects: Arthritis; Biological products; Clinical trials; Immunotherapy; Inhibitor drugs; Monoclonal antibodies; Side effects; TNF inhibitors; Tumor necrosis factor-TNF; Visual impairment
• ISSN: 1759-720X; 1759-7218
• DOI: 10.1177/1759720X211003803

Introduction: Acute anterior uveitis (AAU), affecting up to 40% of patients with axialspondyloarthritis (axSpA), risks permanent visual deficits if not adequatelytreated. We report 2-year results from C-VIEW, the first study toprospectively investigate certolizumab pegol (CZP) on AAU in patients withactive axSpA at high risk of recurrent AAU. Patients and methods: C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safetyfollow-up), open-label, multicenter study. Eligible patients had activeaxSpA, human leukocyte antigen-B27 (HLA-B27) positivity and a history ofrecurrent AAU (⩾2 AAU flares in total; ⩾1 in the year priorto baseline). Patients received CZP 400 mg at weeks 0, 2 and 4, then200 mg every 2 weeks to week 96. The primary efficacyendpoint was the AAU flare event rate during 96 weeks’ CZPversus 2 years pre-baseline. Results: Of 115 enrolled patients, 89 initiated CZP (male: 63%;radiographic/non-radiographic axSpA: 85%/15%; mean disease duration:9.1 years); 83 completed week 96. There was a significant 82%reduction in AAU flare event rate during CZP versuspre-baseline [rate ratio (95% confidence interval): 0.18(0.12–0.28), p